Terminated PHASE4 INTERVENTIONAL 2-arm NCT00856817

Heme Oxygenase (HO) Activity and Adenosine Induced Vasodilation

Sponsor: Dutch Diabetes Research Foundation

Conditions Atherosclerotic Cardiovascular Disease

Interventions Heme arginate + L-arginine L-arginine + heme arginate

Updated 6 times since 2017 Last updated: Aug 10, 2011 Started: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Recruitment faillure. Similar study published by others. Not yet entered treatment phase.

Other Atherosclerotic Cardiovascular Disease trials with similar outcome

NCT05629767 · Jan 2024

Browse all Atherosclerotic Cardiovascular Disease trials

Listed as NCT00856817, this PHASE4 trial focuses on Atherosclerotic Cardiovascular Disease and remains terminated or withdrawn. Sponsored by Dutch Diabetes Research Foundation, it has been updated 6 times since 2009, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Mar 2022 — Jul 2024 [monthly]

Terminated PHASE4
Jan 2021 — Mar 2022 [monthly]

Terminated PHASE4
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE4

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dutch Diabetes Research Foundation
Radboud University Medical Center

Data source: Radboud University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nijmegen, Netherlands